We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$927M
AUM Growth
-$316M
Cap. Flow
-$340M
Cap. Flow %
-36.68%
Top 10 Hldgs %
46.63%
Holding
71
New
14
Increased
9
Reduced
19
Closed
16

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$34.3M
2
PCVX icon
Vaxcyte
PCVX
+$27M
3
CYTK icon
Cytokinetics
CYTK
+$22.3M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.8M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$20.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$58.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33M
3
XNCR icon
Xencor
XNCR
+$28.4M
4
SLN
Silence Therapeutics
SLN
+$23.7M
5
VERA icon
Vera Therapeutics
VERA
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
26
Beam Therapeutics
BEAM
$2.62B
$12.3M 1.32%
+500,000
New +$12.9M
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.48B
$12M 1.3%
+450,000
New +$8.95M
BCYC
28
Bicycle Therapeutics
BCYC
$279M
$11.3M 1.22%
+500,000
New +$11.5M
YMAB
29
DELISTED
Y-mAbs Therapeutics
YMAB
$10.5M 1.14%
+800,000
New +$10.1M
ARVN icon
30
Arvinas
ARVN
$535M
$9.85M 1.06%
+400,000
New +$10.4M
TRVI icon
31
Trevi Therapeutics
TRVI
$2.58B
$9.19M 0.99%
2,750,000
-50,000
-2% -$149K
NUVL
32
DELISTED
Nuvalent
NUVL
$7.67M 0.83%
75,000
-120,000
-62% -$9.95M
CMPS
33
Compass Pathways
CMPS
$1.53B
$7.3M 0.79%
1,159,030
– –
ORKA
34
Oruka Therapeutics
ORKA
$5.52B
$6.31M 0.68%
+257,330
New +$8.95M
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$361M
$6M 0.65%
325,000
-25,000
-7% -$512K
SYRE icon
36
Spyre Therapeutics
SYRE
$8.72B
$5.88M 0.63%
200,000
-375,000
-65% -$10.4M
DYN icon
37
Dyne Therapeutics
DYN
$4.22B
$5.75M 0.62%
160,000
-105,000
-40% -$4.18M
ATXS
38
DELISTED
Astria Therapeutics
ATXS
$5.5M 0.59%
500,000
– –
FULC icon
39
CALL
Fulcrum Therapeutics
FULC
$250M
$5.36M 0.58%
1,500,000
– –
HELP
40
Cybin Inc
HELP
$483M
$5.33M 0.58%
600,000
-452,632
-43% -$4.48M
ENGN icon
41
enGene Therapeutics
ENGN
$121M
$5.28M 0.57%
800,000
-400,000
-33% -$2.98M
AVTX icon
42
Avalo Therapeutics
AVTX
$1.05B
$5.12M 0.55%
539,079
– –
LCTX icon
43
Lineage Cell Therapeutics
LCTX
$259M
$4.53M 0.49%
5,000,000
+300,000
+6% +$278K
RAPP
44
Rapport Therapeutics
RAPP
$2.01B
$4.06M 0.44%
208,910
– –
SLN
45
Silence Therapeutics
SLN
$562M
$3.64M 0.39%
200,000
-1,276,061
-86% -$23.7M
ATYR
46
aTyr Pharma
ATYR
$47.2M
$3.52M 0.38%
2,000,000
-1,000,000
-33% -$1.82M
NXTC icon
47
NextCure
NXTC
$23.1M
$3.42M 0.37%
208,333
– –
ADVM
48
DELISTED
Adverum Biotechnologies
ADVM
$2.92M 0.32%
416,666
– –
ARTV
49
Artiva Biotherapeutics
ARTV
$502M
$2.13M 0.23%
+145,089
New +$1.68M
UNCY icon
50
Unicycive Therapeutics
UNCY
$143M
$2.07M 0.22%
507,893
+160,900
+46% +$646K
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2024 Portfolio in Review

As of Q3 2024, Logos Global Management held 71 positions worth $927M, down 25% from $1.24B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Logos Global Management withdrew a net $340M in Q3 2024, closing 16 positions and reducing 19 holdings. Its most notable exit was argenx, an estimated $58.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 70% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Celldex Therapeutics worth $30.6M.

  • Logos Global Management's largest Q3 2024 buy was Celldex Therapeutics: 900,000 shares worth $30.6M.
  • Logos Global Management added most to Ionis Pharmaceuticals in Q3 2024, an estimated $20.9M increase.
  • Logos Global Management's biggest Q3 2024 reduction was Silence Therapeutics, cutting an estimated $23.7M.
  • Logos Global Management fully exited argenx in Q3 2024, selling an estimated $58.1M.
  • Logos Global Management's ten largest holdings make up 47% of its $927M portfolio in Q3 2024.
  • Logos Global Management opened 14 new positions and closed 16 in Q3 2024.
  • Logos Global Management's portfolio value fell 25% quarter-over-quarter to $927M.

Based on Logos Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.